[Effect of neoadjuvant therapy with neovir on the level of steroid hormone receptors in endometrial cancer tissue].
The effects of neoadjuvant therapy with neovir, provera and their combinations on endometrial tumor morphology, progesterone (PR) and estradiol (ER) receptor levels were studied in 50 patients, aged 40-78, with primary tumors stage I-III, and without concomitant pathology. A 19-day course of neovir did not alter tumor morphological status but was followed by a significant rise in PR and ER concentrations. After neoadjuvant therapy in combination with provera, which generally lowers cytoplasmic receptor levels, mean values of receptors dropped in PR+ tumors while, in PR- tumors, they increased significantly. Our findings suggest that neovir may be used in clinic to stimulate endometrial tumor sensitivity to specific hormonal therapy, particularly, for hormone-independent neoplasia.
Tsyrlina
E V
EV
N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
Bakhidze
E V
EV
Volkova
A T
AT
Kriukova
O G
OG
Chepik
O F
OF
Maksimov
S Ia
SIa
Bershteĭn
L M
LM
D000166:Acridines / Q000627:therapeutic use*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008875:Middle Aged; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D000166:Acridines; D000276:Adjuvants, Immunologic; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C077681:Camedon